J Korean Med Sci.  2017 Aug;32(8):1258-1262. 10.3346/jkms.2017.32.8.1258.

Clinical Impacts of Donor Types of Living vs. Deceased Donors: Predictors of One-Year Mortality in Patients with Liver Transplantation

• Kim EJ
• Lim S
• Chu CW
• Ryu JH
• Yang K
• Park YM
• Choi BH
• Lee TB
• Lee SJ

• KMID: 2439458
• DOI: http://doi.org/10.3346/jkms.2017.32.8.1258

Abstract

Transplantation studies about the clinical differences according to the type of donors are mostly conducted in western countries with rare reports from Asians. The aims of this study were to evaluate the clinical impacts of the type of donor, and the predictors of 1-year mortality in patients who underwent liver transplantation (LT). This study was performed for liver transplant recipients between May 2010 and December 2014 at the Pusan National University Yangsan Hospital. A total of 185 recipients who underwent LT were analyzed. Of the 185 recipients, 109 (58.9%) belonged to the living donor liver transplantation (LDLT) group. The median age was 52.4 years. LDLT recipients had lower model for end-stage liver disease (MELD) score compared with better liver function than deceased donor liver transplantation (DDLT) recipients (mean ± standard deviation [SD], 12.5 ± 8.3 vs. 24.9 ± 11.7, respectively; P < 0.001), and had more advanced hepatocellular carcinoma (HCC) (62.4% vs. 21.1%, respectively; P = 0.001). In complications and clinical outcomes, LDLT recipients showed shorter stay in intensive care unit (ICU) (mean ± SD, 10.8 ± 8.8 vs. 23.0 ± 13.8 days, respectively, P < 0.001), ventilator care days, and post-operative admission days, and lower 1-year mortality (11% vs. 27.6%, respectively, P = 0.004). Bleeding and infectious complications were less in LDLT recipients. Recipients with DDLT (P = 0.004) showed higher mortality in univariate analysis, and multi-logistic regression analysis found higher MELD score and higher pre-operative serum brain natriuretic peptide (BNP) were associated with 1-year mortality. This study may guide improved management before and after LT from donor selection to post-operation follow up.

Keyword

Liver Transplantation; Mortality; Living Donor; BNP; Infection

MeSH Terms

Asian Continental Ancestry Group
Busan
Carcinoma, Hepatocellular
Donor Selection
Follow-Up Studies
Gyeongsangnam-do
Hemorrhage
Humans
Intensive Care Units
Liver Diseases
Liver Transplantation*
Liver*
Living Donors
Mortality*
Natriuretic Peptide, Brain
Tissue Donors*
Transplant Recipients
Ventilators, Mechanical
Natriuretic Peptide, Brain

Reference

1. Shah SA, Levy GA, Greig PD, Smith R, McGilvray ID, Lilly LB, Girgrah N, Cattral MS, Grant DR. Reduced mortality with right-lobe living donor compared to deceased-donor liver transplantation when analyzed from the time of listing. Am J Transplant. 2007; 7:998–1002.

2. Berg CL, Merion RM, Shearon TH, Olthoff KM, Brown RS Jr, Baker TB, Everson GT, Hong JC, Terrault N, Hayashi PH, et al. Liver transplant recipient survival benefit with living donation in the model for endstage liver disease allocation era. Hepatology. 2011; 54:1313–1321.

3. Yaprak O, Dayangac M, Akyildiz M, Demirbas T, Guler N, Bulutcu F, Bassullu N, Akun E, Yuzer Y, Tokat Y. Biliary complications after right lobe living donor liver transplantation: a single-centre experience. HPB (Oxford). 2012; 14:49–53.

4. Reichman TW, Katchman H, Tanaka T, Greig PD, McGilvray ID, Cattral MS, Renner EL, Selzner M, Ghanekar A, Levy G, et al. Living donor versus deceased donor liver transplantation: a surgeon-matched comparison of recipient morbidity and outcomes. Transpl Int. 2013; 26:780–787.

5. Quintini C, Hashimoto K, Uso TD, Miller C. Is there an advantage of living over deceased donation in liver transplantation? Transpl Int. 2013; 26:11–19.

6. Freise CE, Gillespie BW, Koffron AJ, Lok AS, Pruett TL, Emond JC, Fair JH, Fisher RA, Olthoff KM, Trotter JF, et al. Recipient morbidity after living and deceased donor liver transplantation: findings from the A2ALL Retrospective Cohort Study. Am J Transplant. 2008; 8:2569–2579.

7. Merion RM, Shearon TH, Berg CL, Everhart JE, Abecassis MM, Shaked A, Fisher RA, Trotter JF, Brown RS Jr, Terrault NA, et al. Hospitalization rates before and after adult-to-adult living donor or deceased donor liver transplantation. Ann Surg. 2010; 251:542–549.

8. Hoehn RS, Wilson GC, Wima K, Hohmann SF, Midura EF, Woodle ES, Abbott DE, Singhal A, Shah SA. Comparing living donor and deceased donor liver transplantation: A matched national analysis from 2007 to 2012. Liver Transpl. 2014; 20:1347–1355.

9. Akamatsu N, Sugawara Y, Kokudo N. Living donor liver transplantation for patients with hepatocellular carcinoma. Liver Cancer. 2014; 3:108–118.

10. Lo CM. Complications and long-term outcome of living liver donors: a survey of 1,508 cases in five Asian centers. Transplantation. 2003; 75:S12–S15.

11. Lee SG. Asian contribution to living donor liver transplantation. J Gastroenterol Hepatol. 2006; 21:572–574.

12. Wan P, Yu X, Xia Q. Operative outcomes of adult living donor liver transplantation and deceased donor liver transplantation: a systematic review and meta-analysis. Liver Transpl. 2014; 20:425–436.

13. Samstein B, Smith AR, Freise CE, Zimmerman MA, Baker T, Olthoff KM, Fisher RA, Merion RM. Complications and their resolution in recipients of deceased and living donor liver transplants: findings from the A2ALL Cohort Study. Am J Transplant. 2016; 16:594–602.

14. Thuluvath PJ, Yoo HY. Graft and patient survival after adult live donor liver transplantation compared to a matched cohort who received a deceased donor transplantation. Liver Transpl. 2004; 10:1263–1268.

15. Toussaint A, Weiss E, Khoy-Ear L, Janny S, Cohen J, Delefosse D, Guillemet L, Gayat E, Paugam-Burtz C. Prognostic value of preoperative brain natriuretic peptide serum levels in liver transplantation. Transplantation. 2016; 100:819–824.